Day 2 articles


VELETI II: PCI to Intermediate coronary SVG lesions with DES

VELETI II: PCI to Intermediate coronary SVG lesions with DES

Original Title: Sealing intermediate non-obstructive coronary SVG lesions with DES as a new approach to maintaining vein graft patency and reducing cardiac events: the VELETI II randomized clinical trial. Presenter: J. Rodes Cabal.   Non-obstructive SVG lesions affect mid-term prognosis negatively. There is little evidence on the safety and efficacy of non-obstructive intermediate SVG lesions


TR-PCI: Upper Extremity Function Post Transradial PCI

Original Title: Upper extremity function post-transradial (TR)-PCI: interim results. Presenter: Eva Zwaan.   The use of transradial access has increased in the clinical practice thanks to the reduction of vascular and bleeding complications in addition to the shorter time of hospitalization.   The aim of this study was to assess prevalence, magnitude and mechanisms responsible


TriGuard: NeuroProtection Device during TAVI

Original Title: A Patient Level Pooled Analysis of NeuroProtection with the TriGuard Embolic DEFLECTion Device Compared to Unprotected Transcatheter Aortic Valve Replacement. Presenter: Alexandra Lansky   This work was designed to assess the safety and efficacy of the TriGuard device as a complement during transcatheter aortic valve implantation (TAVI) compared to no protection in a

bernardo cortese

MATRIX: Transradial vs. Femoral Access in Non-ST Elevation AMI

Original Title: Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. Presenter: Bernardo Cortese.   The MATRIX study showed that the transradial access is associated with a reduction of combined events, death, infarction, stroke and bleeding, compared to femoral access, in ACS patients. The goal of this sub-analyzis was

Arne Schwindt

FRONTIER II: One Year Outcomes of the New Vascular Closure Device

Original Title: 12-month results of a novel large access closure device: insights from the FRONTIER II Study. Presenter: Arne Schwindt   The FRONTIER II trial assessed the safety and efficacy of the vessel closure device VIVASURE in more than 50 patients using the femoral access for TAVI or aortic endoprosthesis. Puncture site was assessed at

Jens Erik Nielsen-Kudsk

LAA Closure: Preventing Stroke in Patients with Atrial Fibrillation and Prior Intracerebral Hemorrhage

Original Title: LAA occlusion vs. standard care in patients with atrial fibrillation and intracerebral hemorrhage – A propensity score matched follow-up study. Presenter: Jens Erik Nielsen-Kudsk   Patients with atrial fibrillation and a history of intracerebral hemorrhage, have an elevated risk of both ischemic and hemorrhagic stroke. There is no consensus on how to treat